- Home
- BCG vs BLRX Comparison
BCG vs BLRX Comparison
Compare BCG & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCG
- BLRX
- Stock Information
- Founded
- BCG 2016
- BLRX 2003
- Country
- BCG United States
- BLRX Israel
- Employees
- BCG N/A
- BLRX N/A
- Industry
- BCG
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- BCG
- BLRX Health Care
- Exchange
- BCG Nasdaq
- BLRX Nasdaq
- Market Cap
- BCG 45.6M
- BLRX 36.0M
- IPO Year
- BCG N/A
- BLRX 2011
- Fundamental
- Price
- BCG $2.14
- BLRX $0.20
- Analyst Decision
- BCG
- BLRX Strong Buy
- Analyst Count
- BCG 0
- BLRX 2
- Target Price
- BCG N/A
- BLRX $5.50
- AVG Volume (30 Days)
- BCG 67.1K
- BLRX 1.7M
- Earning Date
- BCG 11-14-2024
- BLRX 11-25-2024
- Dividend Yield
- BCG N/A
- BLRX N/A
- EPS Growth
- BCG N/A
- BLRX N/A
- EPS
- BCG N/A
- BLRX N/A
- Revenue
- BCG $161,721,000.00
- BLRX $21,991,000.00
- Revenue This Year
- BCG N/A
- BLRX N/A
- Revenue Next Year
- BCG N/A
- BLRX N/A
- P/E Ratio
- BCG N/A
- BLRX N/A
- Revenue Growth
- BCG N/A
- BLRX N/A
- 52 Week Low
- BCG $1.85
- BLRX $0.19
- 52 Week High
- BCG $16.61
- BLRX $1.68
- Technical
- Relative Strength Index (RSI)
- BCG N/A
- BLRX 25.94
- Support Level
- BCG N/A
- BLRX $0.23
- Resistance Level
- BCG N/A
- BLRX $0.56
- Average True Range (ATR)
- BCG 0.00
- BLRX 0.03
- MACD
- BCG 0.00
- BLRX 0.00
- Stochastic Oscillator
- BCG 0.00
- BLRX 11.82
About BCG Binah Capital Group Inc. Common Stock
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.